A team led by Massachusetts Eye and Ear researchers has identified a novel therapeutic target for retinal neovascularization.
Researchers reportedly found the transcription factor RUNX1 in abnormal retinal blood vessels in tissue taken from patients with proliferative diabetic retinopathy. By inhibiting RUNX1 with a small molecule drug, the researchers reportedly achieved a 50 percent reduction of retinopathy in preclinical models.
According to researchers, their findings may help pave the way for new therapies that address diabetic retinopathy and other conditions involving abnormal vessel growth within the retina.
The study was recently published online in the journal Diabetes.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: Massachusetts Eye and Ear